In Reply I read with a great interest the letter from Salvatore and collaborators commenting on our article1 on the prognostic value of tumor sidedness in patients with stage III colon cancer from the PETACC-8 European trial and its relationship with BRAF and RAS mutational status. We found that while patients with RAS/BRAF wild-type right-sided tumors had a worse disease-free survival, patients with RAS/BRAF-mutant right-sided tumors had a significantly better disease-free survival in comparison with those with left-sided tumors.